Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy.
We report a case of a 17-year-old male with relapse of minimal-change nephrotic syndrome (MCNS), in whom apheresis monotherapy without steroids or immunosuppressants resulted in complete remission. The patient initially developed nephrotic syndrome in February 1998. The first renal biopsy confirmed the diagnosis of MCNS. The patient was also found to be a carrier of hepatitis B virus. Steroid therapy was started with oral prednisolone 60 mg/day. Complete remission was achieved in 3 months, and the steroid treatment was tapered off in May 2001. During the steroid tapering, temporal exacerbation of liver function was noted. In July 2002, the patient was admitted to our hospital again due to relapse of nephrotic syndrome. Second biopsy reconfirmed the diagnosis of MCNS. Since the serum titer of HBV was elevated, apheresis monotherapy was selected to avoid the risk of steroid-induced fulminant hepatitis. Four sessions of low-density lipoprotein apheresis (LDL-A) and 5 sessions of double-filtration plasmapheresis (DFPP) reduced the proteinuria from 9.2 g/day to 0.2 g/day over 38 days without any additional medication. Proteinuria remained suppressed below 0.2 g/day for more than 12 months and no exacerbation of liver function was observed up to the final follow-up in September 2003. The present case suggested the potential of apheresis monotherapy to induce and maintain complete remission of MCNS and an important role of circulating factors in the pathogenesis of MCNS.
Kobayashi
T
T
Department of Nephrology and Pathology, Jichi Medical School, Minamikawachi, Kawachi, Tochigi, Japan.
Ando
Y
Y
Umino
T
T
Miyata
Y
Y
Muto
S
S
Hironaka
M
M
Asano
Y
Y
Kusano
E
E
D000293:Adolescent; D001706:Biopsy; D001781:Blood Component Removal / Q000379:methods; D006801:Humans; D007668:Kidney / Q000473:pathology / Q000648:ultrastructure; D008297:Male; D009402:Nephrosis, Lipoid / Q000628:therapy*; D011507:Proteinuria / Q000628:therapy; D012074:Remission Induction / Q000379:methods; D055502:Secondary Prevention; D012709:Serum Albumin / Q000032:analysis
D012709:Serum Albumin